How to Fight Insurance Denials for Women's Health Treatment

This guide covers appeals for newer women's health therapies that insurers routinely deny: Veozah (fezolinetant) for hot flashes, Zurzuvae (zuranolone) for postpartum depression, Orilissa, Myfembree, and Oriahnn for endometriosis or uterine fibroids, mirabegron and vibegron for overactive bladder, Botox for urge incontinence, Solosec for recurrent bacterial vaginosis, and procedural interventions like uterine artery embolization.

Denials are common because many of these drugs arrived in the past 1–3 years—Veozah in May 2023 as the first non-hormonal neurokinin-3 receptor antagonist for vasomotor symptoms, Zurzuvae in August 2023 as the first oral postpartum depression medication—and insurers have not yet updated coverage policies to reflect pivotal trials or professional-society guidelines. Instead, they impose blanket step-therapy (forcing you to try older, cheaper drugs first) or invoke medical-necessity criteria written before these therapies existed. When your clinician prescribes a $650–720/month medication that works through a novel mechanism, the insurer's computer flags it and issues a template denial citing "experimental," "not medically necessary," or "alternatives available." This guide shows you how to respond with the specific citations, trial names, and clinical arguments that peer-review panels and external reviewers respect.

---

Why Insurers Deny Women's Health Treatments

1. Step-Therapy: "Try Paroxetine, Gabapentin, or SSRIs First"

For Veozah, plans require documented failure of low-dose paroxetine (Brisdelle 7.5 mg) and gabapentin before approving a non-hormonal NK3 antagonist—even when those drugs caused intolerable side effects or you have contraindications to hormone therapy. For Zurzuvae, insurers demand an SSRI or SNRI trial of 6–8 weeks despite postpartum depression's unique biology and the need for rapid symptom control in the first months postpartum.

2. "Hormone Therapy Is First-Line for Menopause"

Plans deny Veozah or non-hormonal options by citing that estrogen-based hormone therapy remains gold-standard for vasomotor symptoms. The denial ignores that you may have a history of venous thromboembolism (VTE), breast cancer, or other absolute contraindications to estrogen—or that you tried hormone therapy and could not tolerate it.

3. "GnRH Agonists (Lupron) Are Standard for Endometriosis and Fibroids"

Insurers deny Orilissa, Myfembree, and Oriahnn by pointing to decades-old leuprolide (Lupron) protocols, which are GnRH agonists. The denial letter does not acknowledge that (a) agonists cause a hormonal flare before suppression, worsening pain for weeks; (b) prolonged GnRH-agonist monotherapy risks severe bone-mineral-density loss; and (c) the newer GnRH antagonists with add-back estrogen/progestin (Myfembree, Oriahnn) were designed to preserve bone and permit longer-term use, as shown in the ELARIS, LIBERTY, and pivotal fibroid trials.

4. "Antimuscarinics Must Be Tried Before Beta-3 Agonists or Botox"

For overactive bladder (OAB), plans require at least two antimuscarinic drugs (oxybutynin, tolterodine, solifenacin) before covering mirabegron (Myrbetriq) or vibegron (Gemtesa)—even when you are elderly, cognitively impaired, or already experienced dry mouth and constipation. Botox (onabotulinumtoxinA) intradetrusor injections are often denied as "cosmetic" or require failure of both antimuscarinics and beta-3 agonists, despite FDA approval and American Urological Association (AUA) / Society of Urodynamics guidelines supporting Botox as second-line.

5. "Single-Dose Antibiotics Are Not Cost-Effective"

Solosec (secnidazole) for bacterial vaginosis is denied because metronidazole or clindamycin gel costs pennies; the insurer ignores that single-dose oral therapy improves adherence and reduces recurrence in women with ≥3 episodes per year, as documented in FDA registration trials.

---

The Citations Insurers Respect

When you appeal, reference these specific guidelines, position statements, and pivotal trials by name and year. Peer-review panels expect them:

Menopause & Vasomotor Symptoms (Veozah, Hormone Therapy)

• The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS): recognizes that systemic hormone therapy is most effective for vasomotor symptoms but lists absolute contraindications (history of breast cancer, VTE, stroke, coronary disease, active liver disease) and acknowledges non-hormonal options—paroxetine, gabapentin, and fezolinetant—as appropriate when estrogen is contraindicated or not tolerated.
• SKYLIGHT-1 and SKYLIGHT-2 trials (Lancet 2023, Menopause 2023): phase-3 randomized controlled trials of fezolinetant 45 mg versus placebo in postmenopausal women with ≥7 moderate-to-severe vasomotor symptoms per day. Both showed statistically significant and clinically meaningful reductions in frequency and severity by week 4 and sustained through 12–52 weeks, with a safety profile free of hormonal or major cardiovascular/VTE signals.
• FDA approval letter May 2023 for Veozah, specifying indication "moderate to severe vasomotor symptoms due to menopause."

Postpartum Depression (Zurzuvae)

• SKYLARK trial (American Journal of Psychiatry 2023): phase-3 RCT of zuranolone 50 mg × 14 days versus placebo in women with postpartum depression (PPD; major depressive episode with onset in third trimester or ≤4 weeks postpartum). Significant reduction in Hamilton Depression Rating Scale (HAM-D) score at day 15 (primary endpoint), sustained through day 45.
• ROBIN trial (JAMA Psychiatry 2023): phase-3 trial in major depressive disorder (not exclusively PPD) showing similar rapid-onset antidepressant effect; supports mechanistic rationale (positive allosteric modulator of GABA-A receptor, distinct from SSRIs).
• FDA approval August 2023 for zuranolone, indicated for postpartum depression in adults; label notes 14-day course and onset within days, versus 4–6 weeks for SSRIs.

Endometriosis (Orilissa, Myfembree)

• ELARIS-EM I and ELARIS-EM II trials (New England Journal of Medicine 2017): elagolix (Orilissa) 150 mg once daily or 200 mg twice daily versus placebo in women with surgically confirmed endometriosis and moderate-to-severe dysmenorrhea or non-menstrual pelvic pain. Both doses significantly reduced pain; higher dose showed greater efficacy but more hypoestrogenic effects (bone loss, hot flashes).
• SPIRIT-1 and SPIRIT-2 trials (Obstetrics & Gynecology 2022): relugolix combination therapy (relugolix 40 mg + estradiol 1 mg + norethindrone 0.5 mg—marketed as Myfembree) versus placebo in endometriosis-associated pain. Combination preserved bone mineral density and reduced vasomotor symptoms compared to GnRH-agonist monotherapy, while maintaining pain efficacy.
• American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin #114 (reaffirmed 2018; updated guidance 2020–2023): acknowledges GnRH agonists and GnRH antagonists (with add-back therapy) as options for moderate-to-severe endometriosis; recommends bone-density monitoring and add-back estrogen/progestin for courses >6 months.

Uterine Fibroids (Myfembree, Oriahnn)

• LIBERTY-1 and LIBERTY-2 trials (New England Journal of Medicine 2020): relugolix combination therapy (Myfembree) in heavy menstrual bleeding (HMB) due to uterine fibroids. ≥50% reduction in menstrual blood loss and control of bleeding in ~70% of women; add-back hormone component mitigated bone loss and vasomotor symptoms.
• ELARIS-UF I and ELARIS-UF II trials (Fertility and Sterility 2020): elagolix + estradiol/norethindrone (Oriahnn) in fibroid-related HMB. Similar efficacy to Myfembree; FDA approved July 2020 for up to 24 months with monitoring.
• ACOG Practice Bulletin #228 (2021): Management of Symptomatic Uterine Leiomyomas: lists GnRH agonists, GnRH antagonists with add-back, levonorgestrel IUD, and uterine artery embolization or myomectomy as evidence-based options; notes that combination GnRH-antagonist therapy reduces hypoestrogenic side effects and permits longer use.

Overactive Bladder (Mirabegron, Vibegron, Botox)

• American Urological Association (AUA) / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline on Non-Neurogenic OAB (2019, amended 2020): recommends behavioral therapy first-line; oral pharmacotherapy (antimuscarinics or beta-3 adrenergic agonists) as second-line, with no preference between antimuscarinics and beta-3 agonists; third-line includes intradetrusor onabotulinumtoxinA (Botox) 100 units.
• SCORPIO trial (European Urology 2013): mirabegron 50 mg versus placebo and tolterodine in OAB. Mirabegron significantly reduced incontinence episodes and urgency, with lower rates of dry mouth than tolterodine.
• FDA labels: mirabegron approved 2012, vibegron 2020, both indicated for OAB (urgency, frequency, urge incontinence); Botox approved for OAB 2013 at 100 units intradetrusor.

Bacterial Vaginosis (Solosec)

• FDA approval 2017 for secnidazole 2-g single-dose oral granules based on phase-3 trials showing non-inferiority to multi-day metronidazole with improved adherence.
• CDC Sexually Transmitted Infections Treatment Guidelines (2021): lists secnidazole as an alternative regimen; single-dose simplifies treatment, particularly for recurrent BV.

---

How to Argue Against Each Denial Reason

"Try Paroxetine and Gabapentin First" (Veozah for Hot Flashes)

Concrete steps:

1. Document prior trials in detail. Write: "Patient completed paroxetine 7.5 mg (Brisdelle) × 12 weeks with only 40% reduction in vasomotor symptom frequency (from 9 to 5.4 moderate-severe hot flashes/day) and persistent severe nocturnal awakenings. Gabapentin 300 mg TID × 8 weeks resulted in intolerable daytime somnolence and dizziness, limiting function."

2. Cite contraindications to hormone therapy if present. Example: "Estrogen-based hormone therapy is contraindicated: history of unprovoked deep-vein thrombosis (DVT) in 2022, per NAMS 2022 Position Statement section on absolute contraindications (VTE within past year, or recurrent/unprovoked VTE)."

3. Invoke SKYLIGHT-1/2 by name. "Fezolinetant (Veozah) demonstrated a median 2.5–3 additional hot-flash reduction per day versus placebo in the SKYLIGHT-1 and SKYLIGHT-2 phase-3 trials (Lancet 2023), with onset by week 4 and durable response to 52 weeks. The neurokinin-3 receptor mechanism does not carry VTE risk."

4. Reference NAMS 2022. "The North American Menopause Society's 2022 Hormone Therapy Position Statement explicitly recognizes fezolinetant as an appropriate non-hormonal option when systemic hormone therapy is contraindicated or not tolerated."

5. Quantify severity with validated instruments. "Baseline Menopause-Specific Quality of Life (MENQOL) vasomotor domain score 7.2 (severe range); Greene Climacteric Scale score 18. Sleep disrupted ≥4 nights/week. After paroxetine/gabapentin trials, patient remains well above clinical thresholds."

Key point: Step-therapy is medically inappropriate when prior steps failed or are contraindicated. Name the trials and the professional-society guideline that supports moving to fezolinetant now.

---

"Hormone Therapy Is First-Line" (Non-Hormonal Options)

Concrete steps:

1. Affirmatively state the contraindication. "Patient has personal history of estrogen-receptor–positive breast cancer (diagnosed 2020, lumpectomy + radiation, currently on aromatase inhibitor). Systemic estrogen is absolutely contraindicated per NAMS 2022 Hormone Therapy Position Statement."

2. Show severity that demands more than lifestyle modification. "Despite behavioral interventions (layered clothing, room temperature control, regular exercise), patient experiences 9–11 moderate-to-severe vasomotor symptoms daily, MENQOL score 7.8, and documented sleep fragmentation (4.2 awakenings/night on sleep diary)."

3. Cite FDA label for Veozah. "Fezolinetant is FDA-approved (May 2023) specifically for moderate-to-severe vasomotor symptoms due to menopause in this exact population—women who cannot or will not take hormone therapy."

4. Attach prior-authorization form and attestation. Many Veozah PAs include a checkbox for "hormone therapy contraindicated or not tolerated." Have your clinician complete it and attach the denial letter as evidence that step-therapy is already documented in your record.

Key point: Hormone therapy being "most effective" does not override an absolute contraindication. NAMS and FDA both recognize non-hormonal options as appropriate first-line therapy when estrogen is off the table.

---

"GnRH Agonists Are Standard" (Orilissa, Myfembree, Oriahnn)

Concrete steps:

1. Distinguish agonist from antagonist. "Leuprolide (Lupron) is a GnRH agonist that causes an initial hormonal flare (worsening endometriosis pain for 2–4 weeks) before sustained suppression. Elagolix (Orilissa) and relugolix (Myfembree, Oriahnn) are GnRH antagonists with immediate suppression and no flare, as demonstrated in ELARIS and LIBERTY trials."

2. Emphasize bone safety with add-back therapy. "Long-term GnRH-agonist monotherapy (>6 months) causes significant bone-mineral-density loss (average −4% to −6% at lumbar spine per year). Myfembree and Oriahnn include add-back estradiol/norethindrone in a single pill, which preserved BMD in the LIBERTY-1/2 and ELARIS-UF trials (mean BMD change ≈−0.8% at 12 months vs. −2.5% with agonist monotherapy)."

3. Cite ACOG. "ACOG Practice Bulletins #114 (endometriosis) and #228 (fibroids) list GnRH antagonists with add-back as evidence-based options; the 2020–2023 updates note that combination therapy mitigates hypoestrogenic effects and supports use beyond 6 months when clinically indicated."

4. Show severity and impact. "Patient has surgically confirmed stage III endometriosis (laparoscopy 2023, American Society for Reproductive Medicine classification). Baseline dysmenorrhea numeric rating scale (NRS) 8/10, non-menstrual pelvic pain NRS 6/10. Failed NSAIDs and combined oral contraceptives (bled through, pain uncontrolled). Requires therapy that permits long-term disease control while preserving bone health for future fertility."

5. Note if you already tried Lupron. If applicable: "Prior leuprolide 3-month depot × 2 cycles resulted in severe vasomotor symptoms (12 hot flashes/day), mood lability, and lumbar spine DEXA T-score decline from −1.0 to −1.8. Could not tolerate beyond 6 months."

Key point: The newer GnRH antagonists with add-back estrogen/progestin are not interchangeable with Lupron. They have distinct mechanisms, improved safety profiles, and trial data supporting longer-term use—data that did not exist when older policies were written.

---

"Antimuscarinics Before Beta-3 Agonists" (Mirabegron, Vibegron)

Concrete steps:

1. Cite the AUA/SUFU 2019 guideline verbatim. "The AUA/SUFU guideline on non-neurogenic overactive bladder (2019, amended 2020) states that clinicians may offer either antimuscarinics or beta-3 adrenergic agonists as second-line oral therapy, with no recommendation of one class over the other. The guideline explicitly notes that drug selection should be individualized based on patient comorbidities and side-effect profile."

2. Document contraindications or intolerance to antimuscarinics. Examples:

- Cognitive risk: "Patient is 78 years old with mild cognitive impairment (MoCA 23/30). Anticholinergic medications (antimuscarinics) carry well-documented risk of worsening cognition and precipitating delirium in older adults, per 2019 AGS Beers Criteria."

- Prior trial: "Tried oxybutynin ER 10 mg × 6 weeks—severe dry mouth and constipation, discontinued. Tolterodine 4 mg ER × 8 weeks—persistent dry mouth, minimal efficacy (still 9 voids/day, 3 urgency incontinence episodes/day)."

3. Quantify OAB severity. "Three-day bladder diary: 11 voids/day, 4 urgency incontinence episodes/day, 2–3 nighttime voids. International Consultation on Incontinence Questionnaire–Overactive Bladder (ICIQ-OAB) score 14 (severe range). Quality of life severely impacted."

4. Reference the SCORPIO trial. "Mirabegron 50 mg showed comparable efficacy to tolterodine 4 mg ER in the SCORPIO phase-3 trial, with significantly lower rates of dry mouth (2.8% vs. 10.1%), supporting use as an equally appropriate first-line oral therapy."

Key point: Insurer step-therapy that mandates antimuscarinic trials contradicts the AUA/SUFU guideline's neutral stance. When antimuscarinics are contraindicated (elderly, cognitive impairment, narrow-angle glaucoma, severe constipation), beta-3 agonists are more appropriate, not "experimental."

---

"Botox Is Cosmetic or Third-Line" (OAB Botox)

Concrete steps:

1. Cite FDA approval and AUA/SUFU. "OnabotulinumtoxinA (Botox) 100 units intradetrusor is FDA-approved (2013) for overactive bladder with symptoms of urge incontinence, urgency, and frequency in adults who have inadequate response or intolerance to anticholinergics. The AUA/SUFU 2019 guideline lists Botox as third-line therapy, meaning it is standard of care after failure of behavioral + one oral medication class."

2. Document oral-therapy trials. "Patient completed tolterodine 4 mg ER × 10 weeks (persistent 8 voids/day, 3 leaks/day, dry mouth). Mirabegron 50 mg × 12 weeks (modest improvement to 7 voids/day, 2 leaks/day, but still severely impacting work as teacher—cannot leave classroom for frequent bathroom breaks). Meets AUA 'inadequate response to oral therapy' criterion."

3. Quantify ongoing severity. "Current ICIQ-OAB score 13. Patient using 4 incontinence pads/day. Avoiding social events and considering job modification. This level of refractory OAB is the exact indication for which Botox received FDA approval."

4. Request peer-to-peer. "Request peer-to-peer review with a urologist or urogynecologist familiar with Botox for OAB. Denial of FDA-approved, guideline-supported third-line therapy after documented failure of behavioral + two oral agents is not consistent with evidence-based practice."

Key point: "Cosmetic" denials are boilerplate errors (insurers see "Botox" and auto-deny). Attach the FDA label and AUA guideline page showing urological indication and second-/third-line status.

---

"Not Medically Necessary" (Zurzuvae for PPD)

Concrete steps:

1. Emphasize postpartum-specific biology and timing. "Postpartum depression (PPD) has a distinct neurobiological mechanism involving rapid hormonal withdrawal and GABAergic system dysregulation, as shown in the SKYLARK and ROBIN trials. Standard SSRIs require 4–6 weeks for onset; in the immediate postpartum period (patient is 6 weeks postpartum), this delay poses significant risk to maternal-infant bonding, breastfeeding success, and infant safety."

2. Cite validated screening scores. "Edinburgh Postnatal Depression Scale (EPDS) score 19 (≥13 indicates probable major depression; ≥10 triggers referral per ACOG guidelines). PHQ-9 score 17 (moderately severe depression). Onset within 4 weeks of delivery, meeting DSM-5 'with peripartum onset' specifier."

3. Reference SKYLARK trial. "Zuranolone (Zurzuvae) demonstrated statistically significant improvement in HAM-D score by day 15 (primary endpoint, AJP 2023), with sustained effect through day 45. This rapid onset is critical in the puerperium when the mother is caring for a newborn and establishing feeding."

4. Note if SSRI is contraindicated or prior failure. Example: "Patient previously took sertraline 100 mg for antenatal anxiety; discontinued at 36 weeks due to neonatal adaptation concerns. Recurrence postpartum is treatment-resistant depression (prior SSRI failure defines this as difficult-to-treat per FDA label for Zurzuvae)."

5. Attach FDA label. "FDA approved zuranolone August 2023 specifically for postpartum depression in adults. The 14-day oral course and rapid onset represent a paradigm shift in PPD treatment. Denial of an FDA-approved drug in its labeled indication is arbitrary."

Key point: Postpartum depression is a medical emergency with unique time constraints. The insurer cannot simply say "try Prozac" when the evidence shows a distinct mechanism and faster onset that directly addresses the clinical urgency of the postpartum period.

---

"Single-Dose Antibiotics Not Cost-Effective" (Solosec for Recurrent BV)

Concrete steps:

1. Quantify recurrence. "Patient has experienced 4 confirmed episodes of bacterial vaginosis in the past 12 months, each treated with metronidazole 500 mg BID × 7 days or metronidazole gel. Recurrence within 4–8 weeks after each course. Amsel criteria met on exam; Nugent score 9 (last episode). This meets 'recurrent BV' (≥3 episodes/year)."

2. Cite adherence data from FDA trials. "Secnidazole (Solosec) 2-g single oral dose achieves 60–70% cure at 4 weeks, non-inferior to 7-day metronidazole, with 100% adherence (single dose). Multi-day metronidazole adherence in real-world studies is ~50%, contributing to recurrence and development of resistance."

3. Note treatment fatigue and quality-of-life impact. "Recurrent BV severely impacts sexual health and quality of life (malodor, discomfort). Patient has repeatedly filled 7-day prescriptions; single-dose therapy would improve adherence and reduce recurrence risk."

4. Reference CDC guidelines. "CDC STI Treatment Guidelines 2021 lists secnidazole as an alternative regimen for BV. In recurrent cases, improved adherence is a clinical rationale for preferring single-dose therapy."

Key point: When recurrence is the problem, the cheapest per-dose regimen is not the most cost-effective if patients don't complete it or relapse repeatedly. Single-dose therapy has unique value in recurrent BV—document the pattern.

---

What We Do

We turn your clinical records, validated severity scores, prior-authorization denials, and prescriber notes into a structured appeal letter that cites the specific professional-society guidelines, pivotal-trial names and outcomes, and FDA approval dates that peer-review panels expect. We draft a physician attestation for your doctor to sign, assemble supporting literature (guideline excerpts, trial abstracts, FDA label pages), and write a patient impact statement that connects the clinical data to your daily life—sleep disruption from hot flashes preventing work performance, postpartum depression symptoms risking maternal-infant bonding, endometriosis pain forcing you to miss workdays, OAB incontinence isolating you socially. We also prepare your case for external review if the internal appeal fails, framing the denial as a deviation from evidence-based care.

If your women's health treatment has been denied, we help you fight back with the medical evidence and procedural expertise to win.

---

Sources

1. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29(7):767–794.

2. Johnson KA, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. Lancet 2023;401(10382):1091–1102. [SKYLIGHT-1]

3. Lederman S, et al. Fezolinetant for vasomotor symptoms associated with menopause: SKYLIGHT-2. Menopause 2023;30(6):598–608.

4. Deligiannidis KM, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. American Journal of Psychiatry 2023;180(9):668–675. [SKYLARK]

5. Clayton AH, et al. Zuranolone for the treatment of adults with major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2023;80(6):677–687. [ROBIN]

6. Taylor HS, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. New England Journal of Medicine 2017;377(1):28–40. [ELARIS-EM I and II]

7. Giudice LC, et al. Once-daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind studies (SPIRIT 1 and 2). Lancet 2022;399(10343):2267–2279.

8. Schlaff WD, et al. Relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids. New England Journal of Medicine 2020;382(4):328–340. [LIBERTY-1 and LIBERTY-2]

9. Archer DF, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 3 trial. Fertility and Sterility 2020;114(2):409–418. [ELARIS-UF I and II]

10. American College of Obstetricians and Gynecologists. Management of endometriosis. Practice Bulletin No. 114. Obstet Gynecol 2010; reaffirmed 2018.

11. American College of Obstetricians and Gynecologists. Management of symptomatic uterine leiomyomas. Practice Bulletin No. 228. Obstet Gynecol 2021;137(6):e100–e115.

12. Gormley EA, et al. Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults: AUA/SUFU guideline amendment 2019. J Urol 2019;202(3):558–563.

13. Chapple CR, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Eur Urol 2014;66(1):4–13. [SCORPIO trial]

14. Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021;70(4):1–187.

15. US Food and Drug Administration. Veozah (fezolinetant) approval letter and label. May 12, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf

16. US Food and Drug Administration. Zurzuvae (zuranolone) approval letter and label. August 4, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216639s000lbl.pdf